Oncology Molecular Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Oncology Molecular Diagnostics Market is Segmented by Product Type (Instrument, Reagents, and Other Product Types), Technology Type (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), DNA Sequencing and Next-Generation Sequencing, In-situ Hybridization, Mass Spectrometry, Transcription Mediated Amplification (TMA), Chips and Microarrays, and Other Technology Types), Application Type (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer, Liver Cancer, Cervical Cancer, and Other Application Types), End User (Hospitals, Diagnostic Centers, and Other End Users), and Geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America).

Oncology Molecular Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Oncology Molecular Diagnostics Industry Overview

The oncology molecular diagnostics market is highly fragmented, with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Danaher Corporation (Cepheid), Veracyte Inc, Abbott Laboratories, F-Hoffmann La-Roche Ltd, and Thermo Fisher Scientific Inc.

Oncology Molecular Diagnostics Market Leaders

  1. Abbott Laboratories

  2. F-Hoffmann La-Roche Ltd

  3. Thermo Fisher Scientific Inc.

  4. Danaher Corporation (Cepheid)

  5. Veracyte Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Market Concentration-OMD market.png

Oncology Molecular Diagnostics Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?